Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,646.40
(
1.31%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
110.80
(
-1.41%
)
Bitcoin
76,336.69
(
0.74%
)
News Focus
News Focus
Post# of 257470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122909
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 240007

Thursday, 11/04/2021 11:24:40 AM

Thursday, November 04, 2021 11:24:40 AM

Post# of 257470
BLUE’s oncology spinoff—“2seventy bio”—begins_ trading_ tomorrow_as ‘TSVT’:

https://www.businesswire.com/news/home/20211104005298/en

BLUE residual gene-therapy company will continue to trade under the ‘BLUE’ ticker.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today